“Cancer drugs that work like heat-seeking missiles to deliver chemicals directly to tumors are having a bit of a moment. Pharmaceutical companies, in need of assets to counter flagging sales, are making these so-called antibody-drug conjugates the technology of choice in oncology dealmaking, as illustrated by last week’s $10.1 billion acquisition of ImmunoGen Inc. by AbbVie Inc. … After decades of fits and starts, the science around designing and testing this class of drugs has finally coalesced. The concept of deploying powerful chemo drugs to cancer cells in a targeted, safer way always made sense; now, companies know how to do it in a manner that could make them a staple of cancer care.”

From Bloomberg.